Shanghai OPM Biosciences Co., Ltd. (SHA:688293)

Market Cap	6.37B +44.6%
Revenue (ttm)	354.91M +22.8%
Net Income	41.70M +13.5%
EPS	0.37 +10.4%
Shares Out	130.04M
PE Ratio	132.35
Forward PE	50.48
Dividend	0.42 (0.86%)
Ex-Dividend Date	Sep 15, 2025

Volume	2,270,399
Average Volume	1,532,448
Open	45.25
Previous Close	45.51
Day's Range	45.25 - 49.97
52-Week Range	31.85 - 67.80
Beta	0.72
RSI	43.81
Earnings Date	Apr 23, 2026

About Shanghai OPM Biosciences

Shanghai OPM Biosciences Co., Ltd. provides cell culture media and CDMO services in China and internationally. The company offers cell culture media and feed supplements, such as OPM's CHO-Platform, OPM-293 Platform, and VegaCHO media and feeds, as well as customized cell culture media development services. It also provides end-to-end biologics CDMO services, such as antibody discovery, stable cell line development, cell banking, upstream process development, downstream process development, formulation development, and quality control and produ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 64
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688293

Financial Performance

In 2024, Shanghai OPM Biosciences's revenue was 297.24 million, an increase of 22.26% compared to the previous year's 243.12 million. Earnings were 21.05 million, a decrease of -61.04%.